The Expressions And Clinical Significance Of NSD2 And EZH2 In Endometrial Carcinoma

[Objective] By detecting the expression of NSD2 and EZH2 in endometrial tissues of endometrial carcinoma, and detecting the expression in complex hyperplasia or non-typical endometrial tissue, normal endometrial tissues. To explore the differences of the NSD2 and EZH2’s expression in these there kinds of endometrial tissues, to analysis the correlation between clinical pathologic factors of patients and the expression of NSD2 and EZH2, and to investigate the correlation between NSD2 and EZH2.To further explore the molecular mechanisms of evolution of the normal endometrial to endometrial carcinoma. Providing new molecular biomarkers to assess the biological characteristics of endometrial carcinoma,clinical treatment and prognosis and tumor targeting gene therapy.[Material and Method] Selecting a total of 42 cases of paraffin-embedded tissue which were diagnosis of endometrial carcinoma by Department of Pathology, Affiliated Hospital of Dali University from January 2011 to December 2015(including : group A is endometrial carcinoma of I type in 32 cases, group B is endometrial carcinoma of II type in 10 cases)as the experimental group; randomly selecting a total of 28 cases of paraffin-embedded tissue due to other diseases such as uterine fibroids and other row hysterectomy or curettage of in the same period(including :group C is 12 cases of complex hyperplasia or non-typical endometrial tissue, group D is 16 cases of normal endometrial) as the control group. All of the selected specimen were confirmed by two pathologists of high qualification, and meet with the World Health Organization(WHO) diagnostic criteria. Immunohistochemistry was used to detect the expression of histone nontransferable EZH2 and NSD2 in the 70 cases of paraffin tissue samples, and analyzed it with the clinical and pathological data.[Results]1、Basic clinical information: the experimental group, 42 cases, age ranging from 31 to 78 years old, with a median age of 56 years old; control group, 28 cases, age ranging from 25 to 68 years old, with a median age of 46 years old. The two sets of clinical data have no significant difference(P> 0. 05), comparable.2, Immunohistochemistry staining results:(1) NSD2 test results: experimental group, 42 cases of EC, the rate of positive expression of NSD2 is 61.90%, group A, group B positive rate are 59.38%, 70.00% respectively. The rate of positive expression of NSD2 in the control group of 28 cases of endometrial tissue is 10.71%, of which group C, group D positive rate are 16.67%, 6.25% respectively. NSD2 significantly expressed in endometrial carcinoma, compared with the control group endometrial, the difference was significant(P = 0.000);NSD2 in type II endometrial carcinoma, I endometrial carcinoma, atypical hyperplasia or complex endometrial hyperplasia and normal endometrial expression tended to increase, there is statistical significance(P =0.000). NSD2 positive expression rates in different age groups, different clinical stage, different degree of differentiation, different muscle infiltration, with or without vascular invasion or lymph node metastasis of endometrial carcinoma patients, the differences are statistically significant(P < 0.05).(2) EZH2 test results: experimental group, 42 cases of EC, the rate of positive expression of EZH2 is 64.29%, group A, group B positive rate are 62.50%, 70.00% respectively. The rate of positive expression of EZH2 in the control group of 28 cases of endometrial tissue is 17.86%, of which group C, group D positive rate are 25.00%, 12.50% respectively. EZH2 significantly expressed in endometrial carcinoma, compared with the control group endometrial, the difference was significant(P = 0.000);EZH2 in type II endometrial carcinoma, I endometrial carcinoma, atypical hyperplasia or complex endometrial hyperplasia and normal endometrial expression tended to increase, there is statistical significance(P =0.000). EZH2 positive expression rates in different age groups, different clinical stage, different degree of differentiation, different muscle infiltration, with or without vascular invasion or lymph node metastasis of endometrial carcinoma patients, the differences are statistically significant(P < 0.05).(3) There is a positive correlation in the expressions of NSD2 and EZH2 in the experimental group(r = 0.773, P = 0. 000). Also the expressions of NSD2 and EZH2 in the control group have a positive correlation(r =0.419, P = 0. 000).[Conclusion]1、The abnormal expression of NSD2 and EZH2 in endometrial carcinoma may be associated with the occurrence and development of endometrial carcinoma,which state that both of them may play a role as a relevant factor in the occurrence of endometrial carcinoma.2、The expressions of NSD2 and EZH2 have a certain relationship with the age, the clinical stage, the tumor differentiation, the depth of myometrial invasion in patients.The malignancy, the development process and the prognosis of endometrial carcinoma are related with NSD2 and EZH2.3、The expressions of NSD2 and EZH2 is consistent in endometrial tissue.There is a positively correlated relationship between the expressions of NSD2 and EZH2 in the development of endometrial carcinoma.